Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer

BACKGROUND: A minority of patients with advanced non-small-cell lung cancer (NSCLC) benefit from treatment with immune checkpoint inhibitors (ICIs). Ineffective effector function of activated T and NK cells may lead to reduced tumor cell death, even when these activated effector cells are released f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurkmans, Daan P., Basak, Edwin A., Schepers, Nina, Oomen-De Hoop, Esther, Van der Leest, Cor H., El Bouazzaoui, Samira, Bins, Sander, Koolen, Stijn L. W., Sleijfer, Stefan, Van der Veldt, Astrid A. M., Debets, Reno, Van Schaik, Ron H. N., Aerts, Joachim G. J. V., Mathijssen, Ron H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254154/
https://www.ncbi.nlm.nih.gov/pubmed/32461348
http://dx.doi.org/10.1136/jitc-2020-000586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254154/
https://www.ncbi.nlm.nih.gov/pubmed/32461348
http://dx.doi.org/10.1136/jitc-2020-000586

Ejemplares similares